Teleflex Inc. 10-Q Summary: Quarter Ended June 26, 2005
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for Teleflex Inc., a diversified industrial company specializing in specialty-engineered products for commercial, medical, and aerospace industries. The report covers the three and six-month periods ended June 26, 2005, compared to the same periods in 2004. The company is currently executing a restructuring and divestiture program to improve operating performance.
Key Financial Metrics
| Metric | Three Months Ended June 26, 2005 |
Six Months Ended June 26, 2005 |
|---|---|---|
| Revenues | $657.96 million | $1,282.50 million |
| Gross Profit | $190.52 million (29.0% margin) | $364.56 million (28.4% margin) |
| Net Income | $28.97 million | $67.70 million |
| Diluted EPS | $0.71 | $1.66 |
| Operating Cash Flow | N/A | $162.91 million |
| Total Debt | $661.82 million | $661.82 million |
| Cash and Equivalents | $212.46 million | $212.46 million |
| Net Debt to Total Capital | 28% | 28% |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 11% in the quarter and 9% for the six-month period compared to 2004. Growth was driven by acquisitions (notably Hudson Respiratory Care Inc.), core growth, and favorable currency impacts, partially offset by dispositions.
- Profitability: Net income for the quarter decreased 15% year-over-year due to restructuring costs and losses from discontinued operations, despite a gain on asset sales in the prior year. However, net income for the six-month period increased 6% due to a $36.1 million gain on the sale of the Sermatech business.
- Restructuring Costs: The company incurred $6.65 million in restructuring charges for the quarter and $13.95 million for the six months, primarily related to the Medical segment (69% of quarterly charges).
- Discontinued Operations: The company reported a loss of $9.34 million from discontinued operations for the quarter, including a $3.1 million impairment charge on a small medical business held for sale.
- Liquidity: Cash and cash equivalents increased significantly from $115.96 million to $212.46 million, driven by strong operating cash flow and proceeds from business sales ($88.9 million).
Guidance, Outlook, and Risks
- Future Restructuring Costs: Management expects to incur an additional $28.0 million to $36.0 million in restructuring costs over the next four quarters, with the majority ($27.2M - $34.0M) allocated to the Medical segment.
- Divestitures: The company signed a definitive agreement in July 2005 to sell its Tier 1 automotive pedal systems business, expected to close in the third quarter. A small medical business is also actively being marketed.
- Stock Repurchase: On July 25, 2005, the Board authorized a $140 million stock repurchase program over the next twelve months.
- Accounting Changes: The company is evaluating the impact of SFAS No. 123(R) regarding stock-based compensation, effective for fiscal years beginning after June 15, 2005. Pro forma EPS under this standard would be lower than reported.
- Risks: Key risks include the ability to integrate acquisitions, execute the restructuring program, manage raw material costs, and resolve ongoing litigation, including a trademark infringement appeal where a $34.8 million jury verdict was previously rejected by a judge.
Investor Verification Checklist
- Verify the timeline and expected proceeds from the pending sale of the automotive pedal systems business.
- Monitor the execution of the restructuring program, specifically the projected $28M-$36M in future costs within the Medical segment.
- Assess the impact of the new SFAS No. 123(R) standard on future earnings per share.
- Review the status of the trademark infringement litigation appeal and potential financial exposure.
- Track the utilization of the newly authorized $140 million stock repurchase program.